KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Gross Profit: 2013-2024

Historic Gross Profit for Supernus Pharmaceuticals (SUPN) over the last 12 years, with Dec 2024 value amounting to $583.9 million.

  • Supernus Pharmaceuticals' Gross Profit rose 9.51% to $173.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $603.9 million, marking a year-over-year increase of 4.02%. This contributed to the annual value of $583.9 million for FY2024, which is 11.49% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Gross Profit of $583.9 million as of FY2024, which was up 11.49% from $523.7 million recorded in FY2023.
  • Supernus Pharmaceuticals' Gross Profit's 5-year high stood at $583.9 million during FY2024, with a 5-year trough of $467.9 million in FY2020.
  • In the last 3 years, Supernus Pharmaceuticals' Gross Profit had a median value of $580.0 million in 2022 and averaged $562.6 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Gross Profit climbed by 24.42% in 2020 and then dropped by 9.70% in 2023.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Gross Profit stood at $467.9 million in 2020, then climbed by 7.86% to $504.7 million in 2021, then increased by 14.92% to $580.0 million in 2022, then dropped by 9.70% to $523.7 million in 2023, then grew by 11.49% to $583.9 million in 2024.